GSK vs PHVS

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Feb 03, 2026

GSK

66.5
AI Score
VS
GSK Wins

PHVS

65.6
AI Score

Investment Advisor Scores

GSK

Feb 03, 2026
67score
Recommendation
BUY

PHVS

Feb 03, 2026
66score
Recommendation
BUY

AI Analyst Insights

Detailed Metrics Comparison

Metric GSK PHVS Winner
Forward P/E 9.5147 0 Tie
PEG Ratio 0.423 0 Tie
Revenue Growth 6.7% 0.0% GSK
Earnings Growth 23.2% 0.0% GSK
Tradestie Score 66.5/100 65.6/100 GSK
Profit Margin 17.1% 0.0% GSK
Beta 1.00 1.00 Tie
Implied Volatility N/A N/A Tie
AI Recommendation BUY BUY Tie

Frequently Asked Questions

Based on our detailed analysis, GSK is currently the stronger investment candidate, winning 4 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.